PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
Could PSMA Be the ‘Bulls-Eye’ Target in mCRPC?
Visit https://www.peervoice.com/GPC860 to view the entire programme with slides. After completing “Could PSMA Be the ‘Bulls-Eye’ Target in mCRPC?”, participants will be able to: Describe the mechanism of the prostate-specific membrane antigen (PSMA) theranostic approach in metastatic castration-resistant prostate cancer (mCRPC); Recall the clinical trials for the development of PSMA radioligand therapy in mCRPC; Identify which patients may be considered candidates for 177Lu-PSMA-617 therapy.